Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) was upgraded by stock analysts at BidaskClub from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday.
Other equities analysts have also issued research reports about the stock. UBS AG began coverage on shares of Alexion Pharmaceuticals in a research report on Wednesday, March 29th. They set a “buy” rating and a $138.00 price target for the company. Stifel Nicolaus reaffirmed a “buy” rating and issued a $157.00 price objective on shares of Alexion Pharmaceuticals in a report on Wednesday, May 24th. Jefferies Group LLC set a $120.00 price objective on shares of Alexion Pharmaceuticals and gave the stock a “hold” rating in a report on Thursday, June 8th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $177.00 price objective on shares of Alexion Pharmaceuticals in a report on Monday, March 27th. Finally, Barclays PLC reissued an “overweight” rating and issued a $155.00 price target on shares of Alexion Pharmaceuticals in a report on Tuesday, May 9th. Seven analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $156.62.
Alexion Pharmaceuticals (NASDAQ ALXN) traded down 0.57% on Tuesday, hitting $130.00. 814,687 shares of the company were exchanged. The stock has a market cap of $29.19 billion, a PE ratio of 61.93 and a beta of 1.38. Alexion Pharmaceuticals has a 52-week low of $96.18 and a 52-week high of $145.41. The firm has a 50 day moving average of $119.82 and a 200-day moving average of $122.82.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.38 EPS for the quarter, topping the consensus estimate of $1.05 by $0.33. The business had revenue of $870 million during the quarter, compared to analyst estimates of $826.63 million. Alexion Pharmaceuticals had a net margin of 14.52% and a return on equity of 11.72%. The company’s quarterly revenue was up 24.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.11 earnings per share. On average, equities analysts expect that Alexion Pharmaceuticals will post $5.33 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://transcriptdaily.com/2017/07/25/bidaskclub-upgrades-alexion-pharmaceuticals-inc-nasdaqalxn-to-buy.html.
In related news, Director Bros. Advisors Lp Baker bought 1,348,955 shares of Alexion Pharmaceuticals stock in a transaction on Wednesday, June 14th. The shares were purchased at an average price of $116.32 per share, for a total transaction of $156,910,445.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Ludwig Hantson bought 10,000 shares of Alexion Pharmaceuticals stock in a transaction on Wednesday, June 14th. The shares were bought at an average price of $116.72 per share, for a total transaction of $1,167,200.00. Following the acquisition, the chief executive officer now owns 38,725 shares of the company’s stock, valued at approximately $4,519,982. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 2,019,734 shares of company stock worth $235,606,846. Company insiders own 4.35% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in ALXN. Dimensional Fund Advisors LP boosted its position in Alexion Pharmaceuticals by 0.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 307,780 shares of the biopharmaceutical company’s stock valued at $37,660,000 after buying an additional 1,385 shares during the period. UBS Asset Management Americas Inc. boosted its position in Alexion Pharmaceuticals by 14.4% in the fourth quarter. UBS Asset Management Americas Inc. now owns 883,694 shares of the biopharmaceutical company’s stock valued at $108,119,000 after buying an additional 111,149 shares during the period. Hudson Bay Capital Management LP acquired a new position in Alexion Pharmaceuticals during the fourth quarter valued at $12,847,000. HighPoint Advisor Group LLC acquired a new position in Alexion Pharmaceuticals during the fourth quarter valued at $529,000. Finally, Kentucky Retirement Systems acquired a new position in Alexion Pharmaceuticals during the fourth quarter valued at $1,991,000. Institutional investors and hedge funds own 94.84% of the company’s stock.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.